Barbara Green, MD
Neurology · Chesterfield, MONPI 1497783997
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $257,773 of the $351,598 with a category attached, or 73.3%. 32 manufacturers reported payments, led by Biogen at 32.3% of the total. Reporting peaked in 2022 at $87,698 and has fallen 90.7% since, to $8,185 in 2025. Among neurology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 667 payments — averaging $527.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$114K
- EMD Serono, Inc.$96K
- Sanofi$37K
- E.r. Squibb & Sons, L.L.C.$20K
- Bristol Myers Squibb$19K
- Genentech USA, Inc.$18K
- plus $49K from 26 others
Across 13 payments — averaging $19,719 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$198K
- F. Hoffmann-la Roche AG$37K
- Novartis$21K
What the payments were for
- Consulting fees$64,05018%
- Speaking & faculty fees$257,77373%
- Travel & lodging$12,7084%
- Food & beverage$16,4785%
- Education$5880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 91 | $113,571 |
| EMD Serono, Inc. | 138 | $95,717 |
| Sanofi | 55 | $36,552 |
| E.r. Squibb & Sons, L.L.C. | 11 | $19,716 |
| Bristol Myers Squibb | 52 | $19,085 |
| Genentech USA, Inc. | 20 | $18,076 |
| Teva Pharmaceuticals USA, Inc. | 13 | $12,225 |
| Vanda Pharmaceuticals Inc. | 10 | $11,874 |
| Johnson & Johnson | 14 | $10,555 |
| Novartis | 167 | $4,945 |
| Greenwich Biosciences, Inc. | 1 | $3,048 |
| TG Therapeutics, Inc. | 6 | $2,275 |
| Banner Life Sciences, LLC | 1 | $900 |
| Janssen Scientific Affairs, LLC | 1 | $850 |
| Amgen(2 entities) | 21 | $547 |
| AbbVie | 14 | $284 |
| AstraZeneca(2 entities) | 9 | $270 |
| Acadia Pharmaceuticals Inc | 14 | $267 |
| Genentech, Inc. | 4 | $199 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $103 |
| Lilly USA, LLC | 4 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Biohaven Pharmaceuticals, Inc. | 1 | $56 |
| Avanir Pharmaceuticals, Inc. | 3 | $53 |
| Pfizer | 3 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
| MDD US Operations, LLC | 2 | $43 |
| Acorda Therapeutics, Inc | 2 | $32 |
| Lundbeck LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$351,598 in reported general payments places this provider in the 95th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 48 | $458,344 |
| AubagioTeriflunomide | 35 | $397,591 |
| MayzentSiponimod | 32 | $273,901 |
| GilenyaFingolimod Hcl | 18 | $265,938 |
| CopaxoneGlatiramer Acetate | 40 | $227,189 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 21 | $173,392 |
| FingolimodFingolimod Hcl | 79 | $109,015 |
| TecfideraDimethyl Fumarate | 12 | $101,609 |
| Teriflunomide | 196 | $94,913 |
| Dimethyl Fumarate | 38 | $70,329 |
| Dalfampridine ErDalfampridine | 228 | $65,661 |
| AmpyraDalfampridine | 13 | $55,853 |
| GlatopaGlatiramer Acetate | 30 | $54,924 |
| MyrbetriqMirabegron | 14 | $13,961 |
| UbrelvyUbrogepant | 13 | $12,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMayzent, Gilenya | $4,945 | $539,83850 claims |
| SanofiAubagio | $36,552 | $397,59135 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $12,225 | $227,18940 claims |
| BiogenTecfidera | $113,571 | $101,60912 claims |
| Acorda Therapeutics, IncAmpyra | $32 | $55,85313 claims |
| AbbVieUbrelvy | $284 | $12,73613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 381 neurology providers in Missouri.
Other neurology in Chesterfield
- William RosenfeldChesterfield$2.1M
- Max BenzaquenChesterfield$105K
- Emily EvansChesterfield$60K
- Zaheer AhmedChesterfield$20K
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Curtis SchreiberBolivar$882K
- Robert NaismithSaint Louis$677K
- Daniel MattsonBridgeton$451K
- Siddharth KaulBridgeton$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.